Canadian patients are waiting on average more than 450 days longer than Americans and Europeans to have access to new medicines that can potentially improve their health or save their lives, according to a study.
The study, published by think tank Fraser Institute on May 13, found that of the 218 drugs approved in both Canada and the United States between the period of 2012/13 and 2018/19, approval was granted on average of 469 days earlier in the United States. When compared with Europe during the same period, the 205 drugs approved had been approved by Europe on average of 468 days earlier than Canada.
